Literature DB >> 23866089

Mechanism of action of ketamine.

Stephen M Stahl.   

Abstract

Ketamine induces rapid-onset and short-duration improvement in depressive and suicidal symptoms in both treatment-resistant unipolar depression and bipolar depression, and also reduces chronic pain after short intravenous infusions. In order to develop long-acting oral agents with the same clinical effects, the pharmacologic mechanism of action must be understood, and the leading hypotheses are discussed here.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23866089     DOI: 10.1017/S109285291300045X

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  8 in total

1.  Use of ketamine in acute cases of suicidality.

Authors:  Jae Lee; Puneet Narang; Manasa Enja; Steven Lippmann
Journal:  Innov Clin Neurosci       Date:  2015 Jan-Feb

Review 2.  Ketamine use in current clinical practice.

Authors:  Mei Gao; Damoon Rejaei; Hong Liu
Journal:  Acta Pharmacol Sin       Date:  2016-03-28       Impact factor: 6.150

Review 3.  Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature.

Authors:  Dawn F Ionescu; Julia M Felicione; Aishwarya Gosai; Cristina Cusin; Philip Shin; Benjamin G Shapero; Thilo Deckersbach
Journal:  Harv Rev Psychiatry       Date:  2018 Nov/Dec       Impact factor: 3.732

4.  Identifying rare variants for genetic risk through a combined pedigree and phenotype approach: application to suicide and asthma.

Authors:  T M Darlington; R Pimentel; K Smith; A V Bakian; L Jerominski; J Cardon; N J Camp; W B Callor; T Grey; M Singleton; M Yandell; P F Renshaw; D A Yurgelun-Todd; D Gray; H Coon
Journal:  Transl Psychiatry       Date:  2014-10-21       Impact factor: 6.222

5.  Effects of Ketamine on Resting-State EEG Activity and Their Relationship to Perceptual/Dissociative Symptoms in Healthy Humans.

Authors:  Sara de la Salle; Joelle Choueiry; Dhrasti Shah; Hayley Bowers; Judy McIntosh; Vadim Ilivitsky; Verner Knott
Journal:  Front Pharmacol       Date:  2016-09-27       Impact factor: 5.810

Review 6.  Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics.

Authors:  Daisy L Spark; Alex Fornito; Christopher J Langmead; Gregory D Stewart
Journal:  Transl Psychiatry       Date:  2022-04-07       Impact factor: 7.989

7.  Intramuscular ketamine vs. escitalopram and aripiprazole in acute and maintenance treatment of patients with treatment-resistant depression: A randomized double-blind clinical trial.

Authors:  Marco Aurélio Cigognini; Alia Garrudo Guirado; Denise van de Meene; Mônica Andréia Schneider; Mônica Sarah Salomon; Vinicius Santana de Alexandria; Juliana Pisseta Adriano; Ana Maria Thaler; Fernando Dos Santos Fernandes; Adriana Carneiro; Ricardo Alberto Moreno
Journal:  Front Psychiatry       Date:  2022-07-22       Impact factor: 5.435

8.  Evidence that Subanesthetic Doses of Ketamine Cause Sustained Disruptions of NMDA and AMPA-Mediated Frontoparietal Connectivity in Humans.

Authors:  Suresh D Muthukumaraswamy; Alexander D Shaw; Laura E Jackson; Judith Hall; Rosalyn Moran; Neeraj Saxena
Journal:  J Neurosci       Date:  2015-08-19       Impact factor: 6.167

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.